iBio, Inc. announced preclinical body composition data from its obese non-human primate study of IBIO-610, showing 6.7% visceral fat reduction and 5.2% total fat mass reduction after two once-every-eight-week doses in a small study. The company updated its corporate presentation describing strategic expansion into the cardiopulmonary space targeting PH-HFpEF with its myostatin x Activin A bispecific antibody program.
Key takeaways
IBIO-610 reduced visceral fat by 6.7% and total fat mass by 5.2% in obese NHPs vs vehicle-treated controls
Study involved two once-every-eight-week dosings of IBIO-610 in small, not statistically powered obese NHP cohort
IBIO-610 showed slight up-tick in lean mass following treatment
Previously reported IBIO-610 half-life of 33.2 days in obese NHPs
Corporate presentation updated to describe expansion into PH-HFpEF using myostatin x Activin A bispecific antibody
Press release issued March 9, 2026, furnished as Exhibit 99.1